Innovate UK has awarded Crescendo Biologics a grant to fund development of drugs combining cytotoxic small molecule payloads with antibody fragments known as Humabodies.
Merck Millipore has entered an agreement whereby it will control and manage the Singulex Life Science Research business, which offers a technology that can provide ultra-sensitive protein detection.
People who work irregular hours get sick more often because proteins that set the human body clock are also involved in DNA repair say US researchers who think drugs targeting the molecules could be used to treat cancer.
Scientists at the Institute for Bioscience and Biotechnology Research (IBBR) are now recommending that biopharma manufacturers use nuclear magnetic resonance (NMR) testing to look for potentially harmful contamination by a group of plant enzymes called...
Analytical and bioanalytical service provider SGS has made significant changes to its global network over the past few months to stay ahead of the competition curve.
UK researchers have created “designer” amino acids which they say will allow them to build custom biologics from the ground up and avoid the pitfalls of recombinant expression.
The US Food and Drug Administration (FDA) has issued guidance on biologics exclusivity, stipulating the evidence drugmakers must provide to ensure a 12-year exclusivity period.
Protein manufacturer Bio-Techne has expanded its purified proteins portfolio through the $60m (€44m) acquisition of antibody developer Novus Biologicals.
Contract manufacturing organisation (CMO) Cobra Biologics is to produce biologics with an increased half-life using a PEGylation platform from biotech QuiaPEG.
Shark antibodies survive in urea concentrations that would denature other proteins thanks to a newly discovered structure that scientists say could be used to make therapeutic mAbs more robust.
Malvern Instruments will buy GE Healthcare’s MicroCal business in a deal that adds protein analysis and formulation development tech to its expanding drug industry offering.
Thermo Fisher Scientific has licensed rights to gene editing technology for bioproduction applications that it claims targets DNA more precisely and reliably than current approaches.
BioAtla has received a broad patent covering conditionally active biologics (CABs) and says this antibody platform could shake up the development of this new class of therapeutics.
Adaptimmune has selected Biolife’s cryopreservation media for its genetically modified T-cell receptor (TCR) product citing its ability to retain viability and potency.
Janssen has asked Novozymes Biopharma to help it reduce drug dosage “from daily to every two weeks or monthly” using its half-life extension technology.
CMO Cytovance Biologics has entered into a manufacturing agreement with Pamlico Biopharma to develop a group of three human IgG monoclonal antibodies intended for the treatment of Streptococcus pneumoniae infections.
Cobra says it will no longer need to rely on third-parties for its biologics quality control tests after receiving an extension to its GMP certification at a Swedish facility.
Last year Octapharma filed the world’s first ‘truly human’ recombinant Factor VIII clotting protein for EMA review and invited BioPharma-Reporter.com to visit the Swedish site where it makes the haemophilia treatment using HEK cells.
Roche has teamed with Molecular Profiles to test if short protein sequences can be used to target conjugated cancer drugs when antibodies prove to large.
Technology firm Upfront Chromatography has exited the biopharmaceutical manufacturing market after selling its protein purification business to Therapure Biopharma.
EMD Millipore on Tuesday launched a new protein A chromatography media to help biopharma manufacturers purify monoclonal antibodies, as well as new prepacked chromatography columns.
Cambridge Research Biochemicals (CRB) has licensed rights to a system that – it claims – will let biopharmas identify the best delivery peptides more quickly.
Agilent Technologies is partnering with SomaLogic to expand the dissemination of Soma’s proteomic assay to at least five academic and contract research centers by the end of the year as demand for the tool has skyrocketed among biopharma companies.
New flexible vaccine technology could pave the way for pneumococcal, TB and staphylococcus aureus vaccines that are cheaper to produce and more effective.
Lonza has granted access to its potency boosting expression system to antibody developer Sorrento Therapeutics just days after a signing a similar deal with Pfizer.
A new genetically modified strain of E. Coli cells could create enough protein for downstream production without the need for the challenging endotoxin removal steps that are currently employed.
AB Sciex is combining its chromatography business with the capillary electrophoresis (CE) business from Beckman Coulter (BC) to align BC’s expertise in microscale separation with AB’s expertise in microfluidics.
Ajinomoto says its flexible approach to tech licensing differs from rivals who are more focused on locking customers into manufacturing services contracts.
Agricultural technology firm Monsanto has partnered with Complix NV to develop the latter’s protein therapeutic targeting technology for crop protection applications.
A new simplified analysis technique of the binding kinetics of membrane proteins could solve a host of drug delivery problems, according to scientists from the Arizona State University.
A new non-glycosolated protein production method using E.coli can cut manufacturing costs by up to 50 per cent as well as speeding up the process, according to researchers at the University of Arkansas.
A new hydrogel which can provide a sustained drug release of up to six months could cut diabetes dosage down from 365 injection per year to just two, according to researchers.
Drug regulators and the biomanufacturing industry need to embrace drug delivery via the skin to solve solubility problems with peptides and proteins, according to Across Barriers’ Udo Bock.
RNA therapeutics developer Arrowhead Research has bought Alvos Therapeutics in the hope that peptide targeting technology will help it overcome delivery challenges.
Custom antibody manufacturer Cambridge Research Biochemicals (CRB) has expanded its range of labelling dyes through a new agreement with supplier Life Technologies.
AIT Bioscience says its new alliance with Perfinity Biosciences will provide protein analysis in 10 minutes, rather than the 48 hours that is standard across the industry.
